Publication
Lenis, Andrew T et al. Clinical cancer research 2024
Authors not recorded
2024PMID 38949888stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CBIOPORTAL-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- cancerMalignant Prostate Neoplasmcbioportal_study1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38949888
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| Immune Checkpoint Inhibitor | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID12987The molecular differences between MSI-H/dMMR and TMB-H/MSS prostate cancer were studied for the impact of these differences on immune checkpoint blockade (ICB) sensitivity. MSI and TMB were studied to… (full text at CIViC) PMID 38949888 · Lenis et al., 2024 · Open in CIViC | civic |